2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|March 1, 2005
- Pharmaceutical Technology-03-01-2005
- Volume 2005 Supplement
- Issue 1
Scale Up of Liquid and Semisolid Manufacturing Processes
The author points out some major obstacles to effective scale-up and describes methods available to pharmaceutical scientists for addressing scalability issues.
Advertisement
Articles in this issue
over 21 years ago
How to Scale Up Scientificallyover 21 years ago
Scale Up of Powder-Blending OperationsAdvertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
Christy Owings, Thermo Fisher, on how AI complements clinical supply chain expertise, streamlines site logistics, and tracks shifting biotech markets.
Christy Owings, Thermo Fisher, speaks on why importer of record strategy and vetted local partners are key to reliable clinical trial supply chains.
Christy Owings, Thermo Fisher, discusses how customs delays and import complexity risk clinical trial supply chains in Latin America.
Advertisement
Advertisement